Skip to content
Screener

Organon OGN Hadlima — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Other Cardiovascular
$28M-6.7%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Lennar logo
LENOther revenues — Revenue
$331.4M-6.8%
PROG Holdings logo
PRGOther Revenues — Revenue
$21.62M+165%
Flanigan's Enterprises logo
BDLOther Revenues — Revenue
$88K+27.5%
American Electric Power logo
AEPCommercial Revenues — Revenue
$1.21B+15.4%
Equinix, Inc. logo
EQIXRecurring revenues — Revenue
$2.38B+10.9%
GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.56B+57.0%
Enterprise value$11.01B+4.2%
P/E6.6×+2.1×
P/S0.6×+0.2×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Organon’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 8:46 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-029532
($ in millions)Three Months Ended March 31, 2025 / U.S.2025 / Int’lTotalU.S.Int’lTotal
General Medicines
Biosimilars
Renflexis421557441257
Hadlima511667331447
Ontruzant41541418
Brenzys—2020—1414
Other Biosimilars (1)111324—55
Established Brands

Item 1. Financial Statements (unaudited)

FAQ

What is Organon's hadlima — revenue?
Organon (OGN) reported hadlima — revenue of $67M in Q1 2026.
How has Organon's hadlima — revenue changed year-over-year?
Organon's hadlima — revenue increased by 42.6% year-over-year, from $47M to $67M.
What is the long-term trend for Organon's hadlima — revenue?
Over 4 years (2021 to 2025), Organon's hadlima — revenue has grown at a 104.9% compound annual growth rate (CAGR), from $13M to $229M.
What does hadlima — revenue mean?
This metric represents the total net sales generated from the Hadlima biosimilar product line. It reflects the market adoption and commercial performance of the company's biosimilar portfolio within the competitive immunology landscape. Tracking this revenue stream provides insight into the company's ability to capture market share from reference biologic products and execute its biosimilar growth strategy.

Ask your AI about Organon's hadlima — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude